Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452412 · ClinicalTrials.gov registry record · Phase 2
Alkali Therapy in Chronic Kidney Disease
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT01452412 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 149 participants.
The verdict
NCT01452412, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
Kidney disease is a common medical condition. Individuals with kidney disease develop a build-up of acid in their blood. This acid can affect their muscles, bones, glucose metabolism and kidneys. The investigators will test alkali treatment, to treat acid build-up, in a randomized placebo-controlled clinical trial to evaluate effects on muscles, bones, glucose metabolism and kidney.
Interventions
- DRUG Placebo
- DRUG Sodium bicarbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01452412
The ClinicalTrials.gov registry entry for NCT01452412 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01452412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01452412 about?
NCT01452412 is a clinical study titled "Alkali Therapy in Chronic Kidney Disease". Kidney disease is a common medical condition. Individuals with kidney disease develop a build-up of acid in their blood. This acid can affect their muscles, bones, glucose metabolism and kidneys. The investigators will test alkali treatment, to treat acid build-up, in a randomized placebo-controlled...
What is the current status of trial NCT01452412?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2011-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01452412?
The interventions under investigation include: Placebo (DRUG), Sodium bicarbonate (DRUG).
Who is sponsoring clinical trial NCT01452412?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.